EXHIBIT 41

Proposed Claim Amendment

(Korean Patent Application No. 2004-7020819)

1. (Currently amended) A pharmaceutical formulation for nasal or ocular administration, which comprises azelastine ~~hydrochloride~~or a pharmaceutically acceptable salt thereofazelastine, ~~or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof,~~ and fluticasonea steroid, or a pharmaceutically acceptable ~~salt, solvate~~esters ~~or physiologically functional derivative~~ thereof, ~~preferably the formulation being in a form suitable for nasal or ocular administration~~.

2. ~~(Cancelled)~~ A pharmaceutical formulation according to claim 1, wherein said azelastine is present as azelastine hydrochloride.

3. (Cancelled) ~~A formulation according to claim 1 or 2, wherein the steroid is beclomethasone or a pharmaceutically acceptable ester thereof, mometasone or a pharmaceutically acceptable ester thereof, fluticasone or a pharmaceutically acceptable ester thereof, budesonide or ciclesonide, in any chiral form or mixture.~~

4. (Cancelled) ~~A formulation according to claim 3, wherein the steroid is beclomethasone propionate, mometasone furoate, mometasone furoate monohydrate, fluticasone propionate or fluticasone valerate.~~

5. (Currently amended) A formulation according to ~~any of~~ claims 1 ~~to 4~~, which contains the fluticasonesteroid in an amount from ~~about~~ 50 micrograms/ml to ~~about~~ 5 mg/ml of the formulation.

6. (Currently amended) A formulation according to ~~any of~~ claims 1 ~~to 5~~, wherein the formulation has a particle size of less than ~~about~~ 10 um~~, preferably less than 5 urn~~.

7. (Currently amended) A formulation according to ~~any of~~ claims 1 ~~to 6~~, which is a suspension containing 0.0005 to 2% (weight/weight of the formulation) of azelastine or a pharmaceutically acceptable salt thereof~~hydrochlorideazelastine or a pharmaceutically acceptable salt of azelastine,~~ and from 0.5 to 1.5% (weight/weight of the formulation) of fluticasone or a pharmaceutically acceptable ester thereof~~said steroid~~.

8. (Currently amended) A formulation according to claim 7, which contains from 0.001 to 1% (weight/weight of the formulation) of azelastine or a pharmaceutically acceptable salt thereof~~hydrochlorideazelastine, or a pharmaceutically acceptable salt thereof,~~ and from 0.5% to 1.5% (weight/weight of the formulation) ~~steroid~~of fluticasone or a

pharmaceutically acceptable ester thereof.

9. (Currently amended) A formulation according to ~~any of~~ claims 1~~ to 8~~, which also contains a surfactant.

10. A formulation according to claim 9, wherein the surfactant comprises a polysorbate or poloxamer surfactant.

11. (Currently amended) A formulation according to claim 9 or 10, which contains from ~~about~~ 50 micrograms to ~~about~~ 1 milligram of surfactant per ml of the formulation.

12. (Currently amended) A formulation according to ~~any of~~ claims 1~~ to 11~~, which also contains an isotonic agent.

13. A formulation according to claim 12, wherein the isotonic agent comprises sodium chloride, saccharose, glucose, glycerine, sorbitol or 1,2-propylene glycol.

14. (Currently amended) A formulation according to ~~any of~~ claims 1~~ to 13~~, which also contains at least one of a buffer, a preservative and a suspending or thickening agent.

15. A formulation according to claim 14, wherein said preservative is selected from edetic acid and its alkali salts, lower alkyl p-hydroxybenzoates, chlorhexidine, phenyl mercury borate, or benzoic acid or a salt, a quaternary ammonium compound, or sorbic acid or a salt thereof.

16. A formulation according to claim 14 or 15, wherein the suspending agent or thickening agent is selected from cellulose derivatives, gelatin, polyvinylpyrrolidone, tragacanth, ethoxose (water soluble binding and thickening agents on the basis of ethyl cellulose), alginic acid, polyvinyl alcohol, polyacrylic acid, or pectin.

17. (Currently amended) A formulation according to ~~any of~~ claims 14~~,15 or 16~~, wherein the buffer comprises a citric acid-citrate buffer.

18. (Currently amended) A formulation according to ~~any of~~ claims 14~~,15, 16 or 17~~, wherein the buffer maintains the pH of the aqueous phase at from 3 to 7~~, preferably 4.5 to about 6.5~~.

19. (Currently amended) A formulation according to ~~any of~~ claims 1~~ to 18~~, which is an aqueous suspension or solution.

20. A formulation according to claim 19, which is in the form of an aerosol, an ointment, eye drops, nasal drops, a nasal spray or an inhalation solution.

21. A formulation according to claim 20, which is in the form of nasal drops or nasal spray.

22. A formulation according to claim 20, which is in the form of an aerosol.

23. A pressure packing having a dosage or metering valve, which contains a formulation according to claim 22.

24. (Currently amended) A ~~MDI~~ metered dose inhaler (MDI) which includes a pressure packing according to claim 23.

25. (Cancelled) ~~A formulation according to any of claims 1 to 19, which is in the form of an insufflation powder.~~

26. (Currently amended) A pharmaceutical product comprising (i) azelastine or a pharmaceutically acceptable salt thereof~~hydrochlorideazelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof,~~ provided in an aerosol formulation ~~preferably~~ together with a propellant ~~typically suitable~~ for metered dose inhaler (MDI) delivery, and (ii) fluticasone~~at least one steroid~~, or a pharmaceutically acceptable ~~salt, solvate~~ or esters ~~physiologically functional derivative~~ thereof, provided in an aerosol formulation ~~preferably~~ together with a propellant ~~typically suitable~~ for MDI delivery, as a combined preparation for simultaneous, separate or sequential use in the treatment of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated.

27. (Currently amended) An aerosol formulation ~~preferably suitable~~ for metered dose inhaler (MDI) delivery comprising (i) azelastine or a pharmaceutically acceptable salt thereof ~~hydrochlorideazelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof,~~ and (ii) fluticasone~~at least one steroid~~, or a pharmaceutically acceptable ~~salt, solvate~~esters ~~or physiologically functional derivative~~ thereof, together with a propellant.

28. (Cancelled) ~~A pharmaceutical product comprising (i) azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, provided as an insufflation powder, and (ii) at least one steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, provided as an insufflation powder, as a combined preparation for simultaneous, separate or sequential use in the treatment of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated.~~

29. (Cancelled) ~~An insufflation powder formulation comprising (i) azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof,~~

~~and (ii) at least one steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, together with a pharmaceutically acceptable carrier or excipient therefor.~~

30. (Cancelled) ~~A pharmaceutical product comprising (i) azelastine, or a pharmaceutically acceptable salt thereof, and (ii) at least one steroid selected from the group consisting of beclomethasone, fluticasone, mometasone and pharmaceutically acceptable esters thereof, as a combined preparation for simultaneous, separate or sequential use in the treatment of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated.~~

31. (Currently amended) A pharmaceutical formulation comprising (i) azelastine or a pharmaceutically acceptable salt thereof ~~hydrochloride~~azelastine, or a ~~pharmaceutically acceptable salt thereof,~~ and (ii) ~~at least one steroid selected from the group consisting of beclomethasone,~~ fluticasone or a pharmaceutically acceptable ester thereof, ~~mometasone and pharmaceutically acceptable esters thereof~~, together with a pharmaceutically acceptable carrier or excipient therefor.

32. (Cancelled) ~~A nasal spray comprising azelastine, or a pharmaceutically acceptable salt thereof, together with mometasone either as mometasone free base or as mometasone furoate, and a pharmaceutically acceptable carrier or excipient therefor.~~

33. (Cancelled) ~~A pharmaceutical product comprising azelastine hydrochloride and beclomethasone dipropionate, as a combined preparation for simultaneous, separate or sequential use in the treatment of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated.~~

34. (Cancelled) ~~A pharmaceutical formulation comprising azelastine hydrochloride and beclomethasone dipropionate, together with a pharmaceutically acceptable carrier or excipient therefor.~~

35. A pharmaceutical product comprising azelastine hydrochloride and fluticasone propionate, as a combined preparation for simultaneous, separate or sequential use in the treatment of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated.

36. A pharmaceutical formulation comprising azelastine hydrochloride and fluticasone propionate, together with a pharmaceutically acceptable carrier or excipient therefor.

37. A pharmaceutical product comprising azelastine hydrochloride and fluticasone

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.